Research Article
[Retracted] Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
Table 1
Comparison of the general information between the two groups.
| | Group | Observation group () | Control group () | |
| | Age (years old) | | 54.45 ± 9.46 | 0.685 | | Pathological types serous adenocarcinoma/mucinous adenocarcinoma/clear cell carcinoma/endometrioid carcinoma/papillary adenocarcinoma/transitional cell carcinoma () | 16/11/5/4/3/2/1 | 14/12/6/5/3/1/1 | 0.875 | | Recurrence site abdominal cavity/pelvic cavity/abdominal pelvic cavity () | 30/10/12 | 16/12/14 | 0.426 | | Clinical stage II/III () | 13/29 | 16/26 | 0.098 |
|
|
